Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.97 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.97 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.97 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.97 |
| ▸ | DPP4 | P27487 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.97 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.97 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.97 |
| ▸ | GAPDH | P04406 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | STAT6 | P42226 | 1/20 | 0.97 |
| ▸ | PI4KA | P42356 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.97 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.97 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.97 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.97 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidarabine SCHEMBL30994790 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL15741481 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL4993136 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL14719528 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL2929 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL1046366 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5078118 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5500833 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10764695 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL27624165 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253733-A1 | RAPAMYCIN CARBONATE ESTERS | BIOINTERACTIONS, LTD. (GB) | 2009-10-08 | — | — | US | claimed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090253733-A1 | RAPAMYCIN CARBONATE ESTERS | BIOINTERACTIONS, LTD. (GB) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | EIF2AK2, MAVS, IRF3 | ADORA3 1742/4885ADORA2A 1896/4885ADORA2B 2377/4885 |
| US-20090253733-A1 | RAPAMYCIN CARBONATE ESTERS | CEL, MTOR, RICTOR | ADORA3 4820/4885ADORA2A 4878/4885ADORA2B 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.